The Science of Savings: Uncovering the Brand-Generic Out-of-Pocket Cost Gap Across Medical Specialties Authors: Andrew Matthews,...

Phase 3 Pooled Analysis of Safety and Efficacy of Trifarotene 0.005% Cream within Adolescent Population Authors: Adelaide Hebert, MD;...

Comparison of Cutaneous Irritation with Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005%...

Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat Authors: Steven R....

Advancement of Personalized Photopneumatic Therapy for Rapid, Visible Improvement in Patients with Mild-to-Moderate Acne Authors: Girish...

Long-Term Safety and Efficacy of Clascoterone Cream 1% in Patients ≥12 Years Old with Acne Vulgaris Authors: Lawrence F. Eichenfield,...

Long-Term Efficacy of Baricitinib in Alopecia Areata: 104-Week Results from BRAVE-AA1 and BRAVE-AA2 Authors: Maryanne Senna, Arash...

Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata from 2 Randomized Clinical Trials Over a Median of 1.6 Years...

Clinical Outcomes for Up-Titration with Baricitinib Therapy in Patients with Severe Alopecia Areata from BRAVE-AA1 and BRAVE-AA2 Authors:...

Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata...

Duration of Current Episode of Alopecia Areata (AA) Influences Prognosis During Treatment with Baricitinib in Patients with Severe AA...

Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) from the Phase 2 and Phase 3 ALLEGRO Clinical Trial...

Impact of Disease History on the Efficacy of Ritlecitinib in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3...

Efinaconazole in the Age of Antifungal Resistance Authors: Ahmed Gamal, Mohammed Elshaer, Lisa Long, Thomas S. McCormick, Boni Elewski,...

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week...

Improvement Across Signs and Symptoms of Atopic Dermatitis with Lebrikizumab Use: Results from Two Phase 3, Randomized, Double-Blinded,...

Lebrikizumab Does Not Impact Vaccine-Induced Immune Responses: Results from A Phase 3 Study in Adult Patients with Moderate-to-Severe...

Assessing Imputation Methods with the Lebrikizumab Clinical Trial Program Authors: April W. Armstrong, Jonathan I. Silverberg, Jacob P....

Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results From 2 Phase 3 Monotherapy...

Patients with Moderate-to-Severe Atopic Dermatitis Experience Heterogeneous Disease Course Phenotypes: Results of a Real-World Study in...

Comparison of Two OTC Itch Relief Products After Single Application Authors: Christine Emesiani, PharmD; Matthew Meckfessel, PhD; Thu...

A Retrospective Multi-Center Case Series of Real-World Tralokinumab Use in Dupilumab-Experienced Patients Authors: Edward I. Herman, MD,...

Long-Term Safety and Efficacy of Tralokinumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: An interim analysis of ECZTEND...

Real-World Patient Characteristics and Early Patient-Reported Outcomes in Adult Patients with Moderate-to-Severe Atopic Dermatitis...